TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01714024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer Trabecular Metal Test Cylinder
Description: For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer Titanium Test Cylinder
Description: For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer Titanium Test Cylinder
Description: For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer Titanium Test Cylinder
Description: For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
Study: NCT01040611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Patients who fit the inclusion criteria were random assigned to either experimental or control group. Patients in experimental group could choose a piece of CD and listen to music with earphone for 30 minutes. Patients in control group just rest for 30 minutes. The procedure was implemented once a day, and sustained for total 5 days.
Study: NCT04255095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experiment
Description: Treatment was randomly selected according to preoperative grouping. After ERCP, naso-pancreatic drainage was chosen as treatment。

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Treatment was randomly selected according to preoperative grouping. After ERCP, nasobiliary drainage was chosen as treatment。
Study: NCT02477384

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 8mm-TIPS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic variceal ligation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 8mm ePTFE-covered stent
Study: NCT02285452

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03541798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positions of patients for combined spinal-epidural anesthesia
Description: Patients in groups will be positioned according to the study groups for performing combined spinal epidural anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positions of patients for combined spinal-epidural anesthesia
Description: Patients in groups will be positioned according to the study groups for performing combined spinal epidural anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: positions of patients for combined spinal-epidural anesthesia
Description: Patients in groups will be positioned according to the study groups for performing combined spinal epidural anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined spinal epidural anesthesia
Description: After positioning, a combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia after identification of subarachnoidal space.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined spinal epidural anesthesia
Description: After positioning, a combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia after identification of subarachnoidal space.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined spinal epidural anesthesia
Description: After positioning, a combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia after identification of subarachnoidal space.
Study: NCT03372018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotora-led Intervention (PLI)
Description: Behavioral life-style program with cognitive-behavioral content lead by a team of trained community health workers (called promotoras) with the following principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (UC)
Description: Participants in this arm will be given educational materials in spanish discussing mental health and diabetes prevention.
Study: NCT01847625

Intervention type: OTHER
Intervention: simulator
Study: NCT04095819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middle Meningeal Artery procedure
Description: Seal off the blood supply to the middle meningeal artery to prevent growth of the Subdural Hematoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Surgery
Description: Drainage of Subdural Hematoma using Craniotomy or Burr Hole
Study: NCT02034227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG2000
Description: intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG2000
Description: intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).
Study: NCT02079389

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lap+Lus
Description: In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection. In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a laparoscopic ultrasound examination of the primary tumor, liver and retroperitoneum.~All patients are given an CT scan of the abdomen after 3 months.
Study: NCT00160446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 5mg Tablet, oral Daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 10 mg Tablet, oral Daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 25 mg Tablet, oral Daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral Daily for 12 weeks
Study: NCT03986918

Intervention type: DEVICE
Intervention: Routine Total Hip Arthroplasty
Description: Patients undergoing routine total hip arthroplasty will receive surveys regarding survivorship and outcomes.
Study: NCT04454619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hand antisepsis with Clorhexidine and solution
Description: Hand antisepsis by scrub Surgical Hand scrubbing using chlorhexidine digluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate. both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hand antisepsis with Clorhexidine and solution
Description: Hand antisepsis by scrub Surgical Hand scrubbing using chlorhexidine digluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate. both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
Study: NCT01320826

Intervention type: PROCEDURE
Intervention: colonoscopy
Description: Data pertaining to all colonoscopies performed by a APC-Endo study physician over a two month period will be collected.
Study: NCT03465982

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery after 8 weeks from chemoradiation treatment
Description: Minimally invasive surgery after 8 weeks from chemoradiation treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery after 12 weeks from chemoradiation treatment
Description: Minimally invasive surgery after 12 weeks from chemoradiation treatment
Study: NCT01415661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cricoid pressure
Description: The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cricoid pressure
Description: The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP.
Study: NCT03951129

Intervention type: PROCEDURE
Intervention: hemodialysis catheter insertion
Description: The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) scoring will be performed after informing all groups and after the procedure
Study: NCT01305135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine and idarubicin
Description: azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine and idarubicin
Description: azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8
Study: NCT00679094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowman-Birk inhibitor concentrate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03193684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: subjects will receive daily dose of 25mg of empagliflozin for 3 months
Study: NCT00679094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03193684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo
Study: NCT02244086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: At the beginning of the work of effective labor maneuver randomly be allocated ( using sealed envelopes) and an outsider to the study prepared the dosage to bupivacaine 0.125% or 0.25% to be administered by epidural catheter for an anesthesiologist to disown the concentration employed. It is measured vital signs, and visual analogue scale dilatation in minutes 0,15,30,60 and 90 after being applied analgesia.
Study: NCT02507115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMAP
Description: Text messages for Alcohol Risk Reduction
Study: NCT04590755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive father-child sessions and website
Description: The Run Daddy Run intervention will consist of 5 (inter)active sessions for fathers and their children + 1 follow-up session, each session lasting 90 minutes. These sessions will be given to 8 groups of +- 13 families (fathers and their children), guided by 2 facilitators and will take place every 2 weeks, at a location in the neighborhood of fathers and children (e.g. school of the children). Additionally, a website will be available for the fathers and their children, with additional information about the project, tips and information about being active together (e.g. movement breaks, fundamental movement skills, etc.) and limiting screen time. In addition, fathers and their children will also log their goals on this website, and between two sessions (= a period of 2 weeks) they will be asked to keep track of their co-PA on this website, aiming to reach their goal.
Study: NCT02507115

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mojo Texts
Description: Motivational texts not alcohol related
Study: NCT02470442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane/Desflurane
Description: Anesthesia induced with sevoflurane and anesthetic maintenance with desflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia induced with sevoflurane and anesthetic maintenance with sevoflurane
Study: NCT03653429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: administered prior to surgical incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: administered prior to surgical incision
Study: NCT03460002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Description: A measles vaccine prequalified from the World Health Organization will be administered in one dose by deep subcutaneous injection into the left subscapular region by a local nurse.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral polio vaccine
Description: A bivalent oral polio vaccine prequalified by the World Health Organization will be administered in one or two doses directly into the mouth of the vaccinee with two drops per dose by a local nurse.
Study: NCT04840303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LevelMind@JC Mental Wellness Youth Hubs
Description: Mental Wellness Youth Hubs Intervention aims to set up a series of community-based hubs for young people to enhance cognitive abilities, personal strengths and overall mental well-being. Among the experimental group participants (hub users), they are further divided into three tiers according to their psychological distress level. Tier 1 are youths with mild psychological distress level, who will be invited to participate in some innovative and interesting youth projects and activities (e.g., board game and floral artistry). Tier 2 are youths who have moderate level of psychological distress, or at risk for mental illness. Trained social workers will offer them with specific interventions (e.g., CBT, sleep intervention) according to their needs. Tier 3 are youths with severe level of psychological distress who are at risk for mental disorders. Diagnostic and medical assessment services will be delivered by psychiatrist or clinical psychologists.
Study: NCT03591692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACAF surgery
Description: The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ACCF surgery
Description: Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
Study: NCT00743353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 RGD-K5
Description: Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
Study: NCT01739465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self expanding metallic stent (SEMS)
Description: Self expanding metallic stent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self expanding metallic stent (SEMS)
Description: Self expanding metallic stent
Study: NCT02566967

Intervention type: DRUG
Group type: OTHER
Intervention: tofacitinib
Description: oral tofacitinib will be taken 2 times daily
Study: NCT04483427

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nalbuphine, ketorolac, accufuser
Description: multimodal analgesic regimen consisting of nalbuphine combined with ketorolac using IV continuous infusion silicon device (Accufuser)
Study: NCT03855462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCT oil injection
Description: The patient treatment is the classical surgical procedure which is used for retinal detachment with MCT oil :~* Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.~* MCT ablation after 4 to 6 weeks (after effective retinopexy)~* after MCT ablation, total follow-up duration by patient is 6 months.
Study: NCT01478945

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 311 nm NB-UVB light
Description: Narrowband UVB is now the most common form of phototherapy used to treat skin diseases. Narrow-band refers to a specific wavelength of ultraviolet (UV) radiation, 311 to 312 nm. Hospital NB-UVB usually involves whole body cabinets suitable for extensive, generalised vitiligo i.e. large or multiple lesions. Usually the whole body is exposed to the UVB for a short time (seconds to minutes). NB-UVB is also used in the treatment of many other skin conditions including psoriasis and eczema.~Hand held phototherapy units use the same lamp as the whole body units (TLO1) but only suitable for the treatment of smaller areas of skin i.e. early and focal lesions of vitiligo.~Early reports showed that these units are also safe and effective for the treatment of psoriasis of the scalp.
Study: NCT03875300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foodwise in Pregnancy
Description: A 7 week programme of nutrition and lifestyle advice, delivered in community venues by trained Healthy Lifestyle Support Workers (HLSWs). Participants must meet study inclusion criteria.
Study: NCT00297882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1. Artemether-Lumefantrine (AL)
Description: Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2. Amodiaquine-Artesunate (AQ-AS)
Description: Amodiaquine-Artesunate (0H),D1(24H),D2(48H)= Artesunate 4mg/kg and Amodiaquine at 10mg/kg
Study: NCT03406611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegtibatinase
Description: Pegtibatinase sterile solution for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline for subcutaneous injection
Study: NCT00590785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
Study: NCT01739465

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self expanding metallic stent (SEMS)
Description: Self expanding metallic stent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic radiofrequency ablation (ERFA)
Description: Endoscopic radiofrequency ablation
Study: NCT01478945

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 311 nm NB-UVB light
Description: Narrowband UVB is now the most common form of phototherapy used to treat skin diseases. Narrow-band refers to a specific wavelength of ultraviolet (UV) radiation, 311 to 312 nm. Hospital NB-UVB usually involves whole body cabinets suitable for extensive, generalised vitiligo i.e. large or multiple lesions. Usually the whole body is exposed to the UVB for a short time (seconds to minutes). NB-UVB is also used in the treatment of many other skin conditions including psoriasis and eczema.~Hand held phototherapy units use the same lamp as the whole body units (TLO1) but only suitable for the treatment of smaller areas of skin i.e. early and focal lesions of vitiligo.~Early reports showed that these units are also safe and effective for the treatment of psoriasis of the scalp.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 311 nm NB-UVB light
Description: Narrowband UVB is now the most common form of phototherapy used to treat skin diseases. Narrow-band refers to a specific wavelength of ultraviolet (UV) radiation, 311 to 312 nm. Hospital NB-UVB usually involves whole body cabinets suitable for extensive, generalised vitiligo i.e. large or multiple lesions. Usually the whole body is exposed to the UVB for a short time (seconds to minutes). NB-UVB is also used in the treatment of many other skin conditions including psoriasis and eczema.~Hand held phototherapy units use the same lamp as the whole body units (TLO1) but only suitable for the treatment of smaller areas of skin i.e. early and focal lesions of vitiligo.~Early reports showed that these units are also safe and effective for the treatment of psoriasis of the scalp.
Study: NCT02673697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perceval valve
Description: Sutureless Aortic Biological Valve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: other stented biological valve
Description: Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)
Study: NCT03280277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo ferumoxytol-enhanced MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV
Study: NCT04170127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irradiation of implants with 635nm laser
Description: Irradiation of implants with 635nm laser
Study: NCT04345146

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FSRT combined with Bevacizumab
Description: Bevacizumab: Patients will receive Bevacizumab (7.5mg/kg, q3w, IV) before and after FSRT.~Fractionated stereotactic radiotherapy(FSRT): 40 Gy/10 fractions or 30 Gy/5 fractions for GTV will be delivered to brain metastases.
Study: NCT01298063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 1 tablet, once qd in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 1 tablet, once qd in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 1 tablet, once qd in the morning
Study: NCT01063205

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration will be started on day 2 and stopped on day 5. Methylsulonylmethane (MSM) will serve as a placebo for MA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Study medication (NAC 1800 mg) will be started on day 2 and stopped on day 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Study medication (NAC 3600 mg) will be started on day 2 and stopped on day 5.